Skip to main content
. 2007 Jun;2(2):169–176.

Table 2.

Main outcomes. Derived from Calverley et al (2003) and Szafransky et al (2003)

C SF (Calverley) FB (Szafranski) S (Calverley) F (Calverley)
Exacerbation RR (vs placebo) 0.70 0.76 0.80 0.81
Symptom-free days 0% 14% 12% 3% 2%

Abbreviations: C, control; F, fluticasone alone; FB, formoterol/budesonide; RR, relative risk; S, salmeterol alone; SF, salmeterol/fluticasone.